Neo-Antigen Therapy Risk Analyzer
7.8
A software platform that assesses the risks associated with emerging neoantigen therapies, particularly mRNA-based treatments, by analyzing clinical trial data, regulatory guidelines, and public sentiment. It would flag potential naming controversies and liability concerns before they impact market perception.
180h
mvp estimate
7.8
viability grade
3
views
technology stack
Python
Medium
PostgreSQL
inspired by
Companies play word games with cancer treatment names.